Rein Therapeutics
RNTX
29 hedge funds and large institutions have $13.5M invested in Rein Therapeutics in 2024 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
26% more funds holding
Funds holding: 23 → 29 (+6)
23% more capital invested
Capital invested by funds: $11M → $13.5M (+$2.54M)
11.86% less ownership
Funds ownership: 34.53% → 22.67% (-12%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
+$7.31M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.22M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.91M |
| 4 |
CCC
Cable Car Capital
San Francisco,
California
|
+$1.73M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
-$5.51M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$89.8K |
| 3 |
Renaissance Technologies
New York
|
-$83K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$1.03K |
| 5 |
IGWM
ICA Group Wealth Management
Denver,
Colorado
|
-$663 |
RNTX Hedge Fund Activity: Q2 2024 in Review
29 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q2 2024, worth a combined $13.5M — up 23% from $11M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RNTX positions and 4 closed out — a net gain of 6 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was University of Texas/Texas AM Investment Management Co (UTIMCO), opening a new position worth an estimated $7.31M. The largest seller was Alerce Investment Management, exiting entirely with an estimated $5.51M sold.
- 29 institutional investors held Rein Therapeutics (RNTX) as of Q2 2024, up from 23 in Q1 2024.
- Funds reported $13.5M of Rein Therapeutics stock for Q2 2024, up 23% quarter-over-quarter.
- 10 funds opened new Rein Therapeutics positions in Q2 2024 and 4 closed out, a net change of +6 holders.
- The largest Rein Therapeutics buyer in Q2 2024 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $7.31M added.
- The largest Rein Therapeutics seller in Q2 2024 was Alerce Investment Management, an estimated $5.51M sold.
Based on aggregated 13F filings for Q2 2024.